Prognostic implications of circulating anti-p53 antibodies in lung cancer - a review

被引:31
作者
Kumar, S. [1 ]
Mohan, A. [1 ]
Guleria, R. [1 ]
机构
[1] All India Inst Med Sci, Dept Med, New Delhi 110029, India
关键词
antigen; survival; therapy; diagnosis; humoral; protein; SERUM P53 ANTIBODIES; GENE MUTATION; CELL; AUTOANTIBODIES; SURVIVAL; METAANALYSIS; CARCINOMA; MARKERS; PROTEIN;
D O I
10.1111/j.1365-2354.2008.01019.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many independent prognostic markers have been identified for predicting survival and helping in the management of lung cancer cases. p53 protein overexpression and mutation have been the topic of numerous such publications. However, little is known about the role of anti-p53 antibodies as a prognostic marker in lung cancer. We searched the MEDLINE database and the bibliographies of the retrieved manuscripts and reviews. The retrieved studies are grouped according to the cohort studied. Out of 179 citations retrieved, 17 met our criteria. Seven studies used only non-small-cell lung cancer; four studies used only small-cell lung cancer; and six studies used the mixed cohort of both types of lung cancer. The studies varied in the concept design, cohort studied and the methodology. The prognostic role of anti-p53 antibodies in lung cancer remains contradictory and as some studies show an association with poor prognosis, others show a favourable association and still others showing no association what so ever. The frequency of detection of anti-p53 antibody is very low, highly specific with result being independent of the cohort studied. Adequate clinical trials, with optimized cohort, antigen and assay validation, are needed to address patients and physician's concerns regarding these associations.
引用
收藏
页码:248 / 254
页数:7
相关论文
共 43 条
[1]   The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival -: art. no. 66 [J].
Bergqvist, M ;
Brattström, D ;
Larsson, A ;
Hesselius, P ;
Brodin, O ;
Wagenius, G .
BMC CANCER, 2004, 4 (1)
[2]  
Bergqvist M, 1998, ANTICANCER RES, V18, P1999
[3]   The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients:: Its implications on tumor volume, nodal involvement, and survival [J].
Bergqvist, M ;
Brattström, D ;
Lamberg, K ;
Hesselius, P ;
Wernlund, J ;
Larsson, A ;
Wagenius, G .
NEOPLASIA, 2003, 5 (04) :283-287
[4]   p53 gene mutation:: software and database [J].
Béroud, C ;
Soussi, T .
NUCLEIC ACIDS RESEARCH, 1998, 26 (01) :200-204
[5]   PROGNOSTIC FACTORS IN LUNG-CANCER - TABLES AND COMMENTS [J].
BUCCHERI, G ;
FERRIGNO, D .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (07) :1350-1364
[6]  
Hammel P, 1999, INT J CANCER, V81, P712, DOI 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO
[7]  
2-0
[8]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[9]   Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies [J].
Huncharek, M ;
Kupelnick, B ;
Geschwind, JF ;
Caubet, JF .
CANCER LETTERS, 2000, 153 (1-2) :219-226
[10]   Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance [J].
Jassem, E ;
Bigda, J ;
Dziadziuszko, R ;
Schlichtholz, B ;
Le Roux, D ;
Grodzki, T ;
Rzyman, W ;
Konopa, K ;
Poberezna, MM ;
Dobrzanska, Z ;
Skokowski, J ;
Soussi, T ;
Jassem, J .
LUNG CANCER, 2001, 31 (01) :17-23